IAPP and Alzheimer disease: Given that impairments in these cognitive domains are signature symptoms of an early stage of AD (Weintraub et al., 2009), both mouse and human studies suggest that amylin, natural or synthetic, are likely to reduce the AD pathology in the brain and provides a new avenue of treatment for the disease.